세계 혈관 성형술용 풍선 및 스텐트 시장 규모는 2024-2030년의 예측 기간 동안 연평균 3.67%를 나타낼 전망입니다. 혈관 성형술용 풍선 및 스텐트 수요는 주로 심혈관 질환(CVD) 환자 증가, 최소침습적 시술에 대한 수요 증가, 약물 코팅/약물 용출성 풍선의 기술 혁신으로 인해 증가하고 있습니다. 또한, 혈관 성형술용 풍선 및 스텐트 시장은 이 분야에서 진행 중인 다양한 연구 활동, 의료 제공업체, 연구자, 업계 진입자의 제휴, 전략적 파트너십 등으로 인해 2024-2030년의 예측 기간 동안 전체 시장 성장에 기여할 것으로 예상됩니다.
혈관 성형술용 풍선 및 스텐트 시장 역학
American Heart Association(2022)의 데이터에 따르면, 2020년 전 세계적으로 약 2억 4,410만 명이 관상동맥(허혈성) 심장질환을 앓고 있다고 합니다.
British Heart Foundation(2022)의 자료에 따르면, 2019년 전 세계적으로 약 5억 5,000만 명(14명 중 1명)이 심장 및 순환기 질환을 앓고 있으며, 여기에는 약 2억 9,000만 명의 여성과 약 2억 6,000만 명의 남성이 포함됩니다. 같은 자료에 따르면 2019년 북미에서는 410만 3,135명이 심혈관 질환을 앓고 있으며, 이 중 108만 9,947명이 관상동맥 질환, 49만 8,551명이 뇌졸중, 아시아에서는 3,237만 6,834명이 심혈관 질환을 앓고 있으며, 이 중 1,254만 3,833명이 관상동맥 질환, 8만 8,833명이 뇌졸중을 앓고 있는 것으로 나타났습니다. 질환을 앓고 있으며, 811만 1,044명이 뇌졸중을 앓고 있는 것으로 나타났습니다.
상기 자료는 또한 관상동맥(허혈성) 심장질환, 말초동맥(혈관) 질환, 뇌졸중, 심방세동이 2019년에도 세계에서 가장 흔하고 유병률이 높은 심혈관 질환으로 나타났습니다고 밝혔습니다.
비만, 고혈압, 당뇨병, 흡연, 고령, 음주, 불건강한 생활습관, 죽상동맥경화증 등 심혈관 질환의 발병을 유발하는 위험요인이 증가함에 따라 혈관 성형술용 풍선 및 스텐트 시장은 더욱 가속화될 것으로 예상됩니다.
WHO(2022)가 제공한 데이터에 따르면 2020년 전 세계 60세 이상 인구는 약 10억 명으로, 2050년까지 60세 이상 노령 인구는 두 배로 증가하여 약 21억 명에 달할 것으로 예측됩니다.
연구에 따르면, PAD의 유병률은 연령에 따라 증가하여 60세 미만의 3%에서 발병하며, 70세 이상에서는 15-20%까지 증가한다고 합니다.
따라서, 위의 요인들로 인해 혈관 성형술용 풍선 및 스텐트 시장은 예측 기간 동안 성장할 것으로 추정됩니다.
그러나 엄격한 규제 절차로 인한 부작용과 제품 리콜로 인해 전체 혈관 성형술용 풍선 및 스텐트 시장의 성장이 억제될 수 있습니다.
혈관 성형술용 풍선 및 스텐트 시장의 부문 분석
혈관 성형술용 풍선 및 스텐트 시장의 풍선 카테고리 제품 유형 부문에서는 2023년 약물 코팅 풍선이 큰 매출 점유율을 차지할 것으로 예상됩니다.
관상동맥질환 및 말초동맥질환 치료에서 약물 코팅 풍선의 장점과 용도는 그 수요를 증가시킬 것으로 예상됩니다.
약물 코팅 풍선(DCB) 혈관성형술은 기존의 풍선 혈관성형술(POAB)과 시술상 동일하지만, 풍선에 항증식제와 부형제를 코팅하여 약물 전달을 촉진하는 것이 특징입니다.
약물 코팅 풍선은 재협착을 예방하는 데 도움이 될 수 있습니다. 약물 코팅 풍선을 사용하면 세포 분열을 억제하여 치료 후 재협착, 즉 막힘의 재생 정도를 줄일 수 있습니다.
DCB 혈관성형술 시 이물질을 삽입하지 않음으로써 환자의 신체는 관상동맥의 원래 해부학적 구조의 변화를 피할 수 있을 뿐만 아니라, 후기 스텐트 혈전증이나 알레르기 등의 위험으로부터도 벗어날 수 있습니다.
또한, 특히 젊은 환자의 경우, 수술적 치료나 중재적 치료의 가능성이 더욱 높아질 수 있습니다.
이 보고서는 세계 혈관 성형술용 풍선 및 스텐트 시장에 대해 조사 분석했으며, 시장 규모와 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 전해드립니다.
The Angioplasty Balloons And Stents Market By Product Type (Balloons [Drug-Coated Balloons And Plain Old Balloons], Stents [Drug-Eluting Stents And Bare Metal Stents]), Indication (Coronary Artery Disease And Peripheral Artery Disease), End-User (Hospitals, Ambulatory Surgical Centers, And Cath Labs), and geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing number of cases of urinary tract infections (UTI) and increasing research and development activities
The global angioplasty balloons and stents market is estimated to grow at a CAGR of 3.67% during the forecast period from 2024 to 2030. The demand for angioplasty balloons and stents is primarily being boosted by the increasing number of people with cardiovascular diseases (CVDs), the rise in demand for minimally invasive procedures, growing innovations in drug-coated/drug-eluting balloons, and others. Furthermore, the angioplasty balloons and stents market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the angioplasty balloons and stents market during the forecast period from 2024-2030.
Angioplasty Balloons And Stents Market Dynamics:
According to American Heart Association 2022 data, globally about 244.1 million people were living with coronary (ischemic) heart disease in 2020.
As per the data provided by British Heart Foundation 2022, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men. As per the same source, in 2019, in North America, cardiovascular diseases affected 4,103,135 people, 1,089,947 people were diagnosed with coronary artery disease, and 498,551 suffered from stroke; In Asia, there were 32,376,834 people diagnosed with cardiovascular diseases, from which 12,543,833 individuals were affected by coronary artery disease, and 8,111,044 population was suffered from a stroke.
The source mentioned above further stated that coronary (ischemic) heart disease (200 million cases), peripheral arterial (vascular) disease (110 million cases), stroke (100 million cases), and atrial fibrillation (60 million cases) remained the commonest and prevalent cardiovascular conditions worldwide in 2019.
The increasing number of risk factors such as obesity, hypertension, diabetes, smoking, old age, alcohol consumption, unhealthy lifestyle, atherosclerosis, and others causing the development of cardiovascular diseases in one way or another are further going to accelerate the market for angioplasty balloons and stents.
According to the data provided by the WHO (2022), in 2020, about one billion people across the world were over the age of 60. The source mentioned above added by stating that by 2050, the elderly population aged 60 and above is expected to double in number representing about 2.1 billion people.
As per research studies, the prevalence of PAD increases with age; it occurs in 3% of people <60 years, but its prevalence increases to 15% to 20% among individuals >70 years.
Thus, owing to the above-mentioned factors, the angioplasty balloons and stents market is estimated to grow during the forecast period.
However, stringent regulatory procedures adverse effects, and product recalls may restrict the growth of the overall angioplasty balloons and stents market.
Angioplasty Balloons And Stents Market Segment Analysis:
Angioplasty Balloons and Stents Market By Product Type (Balloons [Drug-Coated Balloons and Plain Old Balloons], Stents [Drug-Eluting Stents and Bare Metal Stents]), Indication (Coronary Artery Disease and Peripheral Artery Disease), End-User (Hospitals, Ambulatory Surgical Centers, and Cath Labs), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment under the balloons category of the Angioplasty Balloons and Stents market, the drug-coated balloons, category is expected to amass a significant revenue share in the year 2023.
The advantages and applications associated with drug-coated balloons in the treatment of coronary artery disease and peripheral artery disease are going to increase their demand.
Procedure-wise, Drug-Coated Balloon (DCB) angioplasty is comparable to Plain Old Balloon Angioplasty (POAB), but it includes coating the balloon with an anti-proliferative medicine and an excipient to facilitate drug transfer.
Drug-coated balloons aid in the prevention of restenosis, which is the vessel's re-narrowing at a previously treated spot. Employing a balloon coated with medication may prevent cell division, thereby reducing the degree of restenosis, or blockage regrowth, following therapy.
By not implanting a foreign body during the DCB angioplasty, the patient's body is spared from modifications to the coronary artery's original anatomical structure as well as risks such as late stent thrombosis and allergy.
Additionally, it offers chances for further surgical treatment or interventional therapy, especially for young patients.
The interventional process is comparatively easy, requiring less time to complete and exposing patients and medical personnel to less radiation.
By uniformly distributing the medication to the blood vessel's inner wall, DCB can prevent the delayed endothelialization brought on by the unequal dispersion of stent metal rods.
By applying DCB, the duration of dual antiplatelet medication can be shortened, and the risk of bleeding and other problems can be decreased.
For certain kinds of lesions, such as narrow lesions, high bleeding risk lesions, patients with diabetes, etc., DCB may be a better option than stent insertion.
Thus, all the above-mentioned factors are likely to propel the market for drug-coated balloons in Angioplasty Balloons and Stents.
North America is expected to dominate the overall Angioplasty Balloons And Stents Market:
Among all the regions, North America is estimated to account for the largest share of the Angioplasty Balloons and Stents market in the year 2023. This domination is due to the increasing application of angioplasty balloons and stents in the treatment and management of peripheral and coronary artery disease which are on the rise in the region, increasing sedentary lifestyle, anxiety, and stress resulting in chronic diseases, such as diabetes and obesity, leading to an increase in the prevalence of multiple cardiovascular diseases, rising product launch and approvals, presence of favorable regulatory authority, among others will propel the market of angioplasty balloons and stents in the US.
For instance, as per the study conducted by the Centre for Disease Control and Prevention (CDC) in 2023, it was stated that in 2021, about 1 in 20 adults age 20 and older have coronary artery disease (CAD). Coronary heart disease is the most common type of heart disease in the US, killing 375,476 people in 2021. In 2021, about 2 in 10 deaths from CAD happened in adults less than 65 years old. Thus, the high burden of cardiovascular diseases in the region demands the availability of drug-eluting balloons.
The American Heart Association in the latest study estimated that over 500,000 percutaneous coronary intervention (PCI) procedures are carried out annually in the US. Percutaneous coronary intervention with a drug-coated balloon (DCB) is a novel treatment that seeks to acutely dilate coronary stenosis and deliver an anti-proliferative drug to the vessel wall. Thus, the number of PCI procedures in the region will increase the demand for drug-eluting balloons.
Further, the availability of various major manufacturers, the launch and approval of new and technologically advanced devices, and favorable reimbursement regulations are all important factors responsible for driving the demand for drug-eluting balloons in the region. For instance, in November 2022, Genesis MedTech Group announced that the Food and Drug Administration (FDA) has approved the Chocolate Touch(R) Drug-coated Balloon PTA Catheter, developed by TriReme Medical LLC, for the treatment of patients with peripheral artery disease in the superficial femoral artery and the popliteal artery.
Thus, the above-mentioned factors are likely to propel the growth of the angioplasty balloons and stents market in the region during the forecast period from 2024-2030.
Angioplasty Balloons And Stents Market Key Players:
Some of the key market players operating in the Angioplasty Balloons and Stents market include B. Braun SE, BIOTRONIK, Medtronic, Abbott, Boston Scientific Corporation, Cook, Biosensors International Group, Ltd., MicroPort Scientific Corporation, Terumo Corporation, Demax Medical Technology, BD, BrosMed Medical Co., Ltd., Cordis, Sino Medical Sciences Technology Inc., Concept Medical, and Others.
Recent Developmental Activities in the Angioplasty Balloons And Stents Market:
Key Takeaways from the Angioplasty Balloons And Stents Market Report Study
Target Audience who can be benefited from this Angioplasty Balloons And Stents Market Report Study
Frequently Asked Questions for the Angioplasty Balloons And Stents Market:
Angioplasty Balloons and Stents are intended for the effective treatment of coronary and peripheral artery disease by opening a narrowed or blocked artery.
The global angioplasty balloons and stents market is estimated to grow at a CAGR of 3.67% during the forecast period from 2024 to 2030.
The demand for angioplasty balloons and stents is primarily being boosted by the increasing number of people with cardiovascular diseases (CVDs), the rise in demand for minimally invasive procedures, growing innovations in drug-coated/drug-eluting balloons, and others. Furthermore, the angioplasty balloons and stents market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the angioplasty balloons and stents market during the forecast period from 2024-2030.
Some of the key market players operating in the angioplasty balloons and stents market include B. Braun SE, BIOTRONIK, Medtronic, Abbott, Boston Scientific Corporation, Cook, Biosensors International Group, Ltd., MicroPort Scientific Corporation, Terumo Corporation, Demax Medical Technology, BD, BrosMed Medical Co., Ltd., Cordis, Sino Medical Sciences Technology Inc., Concept Medical, and Others.
North America is expected to dominate the overall Angioplasty Balloons and Stents market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the increasing patient pool with peripheral and coronary artery disease, increasing sedentary lifestyle, anxiety, and stress resulting in chronic diseases, such as diabetes and obesity, leading to an increase in the prevalence of multiple cardiovascular diseases. Further, rising product launches and approvals and, the presence of favorable regulatory authority, among others will propel the market of angioplasty balloons and stents in the US.